
Dr. Lal Pathlabs’ stock price rose nearly 3% following an upgrade by CLSA to “Outperform” with a revised target price of ₹3,240. As of 10:03 AM, the shares were trading 2.46% higher at Rs 2,912.70.
CLSA highlighted key drivers for the upgrade, including improved volume growth, which has bottomed out in FY24, and stable pricing trends.
Despite a 22% drop from its previous high, CLSA believes the decline is overdone. The stock now trades at a discount compared to its peers, a shift from the premium it once commanded. At ₹2,847.85, Dr. Lal Pathlabs is trading around 12% below CLSA’s target price of ₹3,240.
Dr. Lal Pathlabs shares opened at ₹2,870, reaching a high of ₹2,919.75 and a low of ₹2,864.05 today. Over the past year, the stock has fluctuated between a 52-week high of ₹3,653.95 and a low of ₹1,943.70.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.